https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
018), and immunosuppression (p = 0.039). Midface location, patient compliance, and diagnosis method were codependent variables (r = 0.2011, p = 0.0008). All BCCs (119/119) demonstrated complete clinical and subclinical tumor clearance 2 months after final laser treatment. By 1 year, overall clinical recurrence rate (RR) was 1.7% (2/119) and cumulative subclinical RR was 4.2% (5/119). Upon excluding immunosuppressed patients, clinical RR and combined subclinical RR for primary BCC were 1% (1/98) and 2% (2/98), respectively,
Like
Comment
Share
